Update on therapeutic options for multiple sclerosis

Neurologic Clinics

Volumn 31, Issue 3, 2013, Pages 827-845

  McCoyd, Matthew ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alemtuzumab (Lemtrada); BG 12 (Tecfidera); Fingolimod (Gilenya); McDonald criteria; Natalizumab (Tysabri); Teriflunomide (Aubagio); Vitamin D

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; CORTICOTROPIN; CYCLOPHOSPHAMIDE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PREDNISONE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TERIFLUNOMIDE; VITAMIN D;

ALTERNATIVE MEDICINE; ASPIRATION PNEUMONIA; BLOOD BRAIN BARRIER; CLINICAL DECISION MAKING; CLINICAL FEATURE; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FLUSHING; FOOD AND DRUG ADMINISTRATION; HAIR LOSS; HERPES SIMPLEX ENCEPHALITIS; HERPES ZOSTER; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MOLECULAR MIMICRY; MULTIPLE SCLEROSIS; NAUSEA; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RELAPSE; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; SUICIDE; SYSTOLIC BLOOD PRESSURE; TABLET; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VITAMIN SUPPLEMENTATION;

EID: 84881030183     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2013.03.010     Document Type: Review

References (78)

1. Compston A., Lassmann H., McDonald I. The Story of Multiple Sclerosis. McAlpine's Multiple Sclerosis 2006, 1-68. Elsevier, Philadelphia. 4th Edition. A. Compston, C. Confavreux, Lassmann (Eds.).
2. The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661.
3. Paty D.W., Li D.K. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: MRI results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:662-667.
4. Arnason B.G. Interferon beta in multiple sclerosis. Neurology 1993, 43:641-643.
5. Schumacher F.A., Beeve G.W., Kibler R.F., et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials in multiple sclerosis. Ann N Y Acad Sci 1965, 122:552-568.
6. Young I.R., Hall A.S., Pallis C.A., et al. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet 1981, 8255:1063-1066.
7. Poser C.M., Paty D.W., Schelenberg L.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983, 1:227-231.
8. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
9. Polman C.H., Reingold S.C., Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria. Ann Neurol 2005, 58:840-846.
10. Polman C.H., Reingold S.C., Banwell B., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69:292-302.
11. Barkhof F., Filippi M., Miller D.H., et al. Comparison of MRI imaging criteria at first presentation to predict conversion to clinically definite MS. Brain 1997, 120:2059-2069.
12. Tintore M., Rovira A., Martinez M., et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000, 21:702-706.
13. Swanton J.K., Fernando K., Dalton C.M., et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndrome. JNeurol Neurosurg Psychiatry 2006, 77:830-833.
14. Selchen D., Bhan V., Blevins G., et al. MS, MRI and the 2010 McDonald criteria: a Canadian expert commentary. Neurology 2012, 79(Suppl 2):S1-S13.
15. Uitdehaag B.M., Barkof F., Coyle P.K., et al. The changing face of multiple sclerosis clinical trial populations. Curr Med Res Opin 2011, 27:1529-1537.
16. Klawiter E.C., Cross A.H., Naismith R.T. The present efficacy of multiple sclerosis therapeutics: is the new 66% just the old 33%?. Neurology 2009, 73:984-990.
17. Weiner H.L. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 2004, 61:1613-1615.
18. Chaudhuri A., Behan P.O. Multiple sclerosis is not an autoimmune disease. Arch Neurol 2004, 61:1610-1612.
19. Bar-Or A. The immunology of multiple sclerosis. Semin Neurol 2008, 28:29-45.
20. Dhib-Jalbut S. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology 2007, 68(Suppl 3):S13-S21.
21. Racke M.K. Update on the pathogenesis of multiple sclerosis. Adv Stud Med 2008, 8(5):137-143.
22. Kowarick M.C., Pellkofer H.L., Cepok S., et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011, 76:1214-1221.
23. Mehling M., Johnson T.A., Antel J., et al. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 2011, 76(Suppl 3):S20-S27.
24. Kappos L., Radue E.W., O'Connor P., FREEDOMS Study Group, et al. Aplacebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. NEngl J Med 2010, 362:387-401.
25. Cohen J.A., Barkhof F., Comi G., TRANSFORMS Study Group, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. NEngl J Med 2010, 362:402-415.
26. Efficacy and Safety of Fingolimod (FTY720) in Patients with Relapsing-remitting Multiple Sclerosis (FREEDOMS II). Available at:. Accessed April 11, 2013. http://clinicaltrials.gov/ct2/show/results/NCT00355134%3fsect=X615#part.
27. Calabresi P.A., Radue E.W., Goodin D, etal. Efficacy and safety of fingolimod in patients with relapsing multiple sclerosis (RRMS): Results from an additional 24-month double-blind, placebo-controlled study (FREEDOMS II study). In: 64th American Academy of Neurology Annual Meeting. Emerging Science Session, New Orleans (LA) 2012. p. 015.
28. Hashmonay R, Kappos L, Cohen JA, etal. Consistent efficacy of fingolimod across clinical development program. In: 4th Corporation Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclorosis, San Diego (CA). 2012. p. DX68.
29. Jeffrey, S. PML Reported in MS Patient on Fingolimod. Available at:. Accessed April 16, 2013. http://www.medscape.com/viewarticle/762039.
30. Cohen J.A., O'Conner P., Caliolo T., etal. Long term safety of fingolimod in relapsing multiple sclerosis: update to integrated analyses of phase 2 and 3 studies and extension phases. In: 28th Congress of the European Treatment and Research in Multiple Sclerosis (ECTRIMS). Lyon, France. 2012. p. 983.
31. Schwab P., Zhou Y., Stemkowski S., etal. Analysis of first dose observation data for MS treatment with fingolimod. In: Fourth Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS). San Diego, CA 2012.
32. Samson K. Health officials launch investigation in death of patients taking fingolimod. Neurology Today 2012;12(4):27-28. Available at:. Accessed April 11, 2013. http://www.aan.com/elibrary/neurologytoday/%3fevent%3dhome.showArticle%26id%3dovid.com:/bib/ovftdb/00132985-201202160-00001.
33. FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). Available at:. Accessed April 11, 2013. http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm.
34. Jain N., Bhatti M.T. Fingolimod-associated macular edema: incidence, detection, and management. Neurology 2012, 78:672-680.
35. O'Connor P., Wolinsky J., Confavreux C., et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. NEngl J Med 2011, 365:1293-1303.
36. Miller A, Turpault S, Menguy-Vacheron F. Rapid elimination procedure of teriflunomide with cholestyramine or activated charcoal. In: 17th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis. San Diego, CA: p. 10.
37. Results from second phase III study of teriflunomide show reduced relapse rate, slower progression of disability. Available at:. Accessed April 16, 2013. http://www.businesswire.com/news/home/20121012005423/en/Genzyme-Presents-Phase-III-Study-Once-daily-Oral.
38. Phase III study with teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis (TOPIC). Available at:. Accessed April 11, 2013. http://clinicaltrials.gov/ct2/show/results/NCT00622700.
39. Freedman M.S., Confavreux C., Comi G., etal. Hair thinning associated with teriflunomide therapy is manageable. In: 17th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis. San Diego, CA June, 2012.
40. Chambers C.D., Tutuncu Z.N., Johnson D., et al. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther 2006, 8:225-235.
41. Chambers C.D., Johnson D.L., Robinson L.K., et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010, 62:1494-1503.
42. Cassina M., Johnson D.L., Robinson L.K., et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 2012, 64:2085-2094.
43. Kieseier B., Benamor M., Benzerdjeb H., etal. Pregnancy outcomes from the teriflunomide clinical development programme: retrospective analysis of the teriflunomide clinical trial database. In: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France. p. 737.
44. Genzyme reports top-line results for TENERE study of oral teriflunomide in relapsing multiple sclerosis. Available at:. Accessed April 11, 2013. http://www.businesswire.com/news/home/20111219006550/en/Genzyme-Report-Top-line-Results-TENERE.
45. Gold R., Kappos L., Arnold D.L., et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. NEngl J Med 2012, 367:1098-1107.
46. Kappos L., Gold R., Miller D.H., et al. Efficacy and safety of oral fumarate in patients with relapsing remitting multiple sclerosis: a multicenter randomized double blind, placebo-controlled phase IIb study. Lancet 2008, 367(12):1463-1472.
47. Ropper A.H. The "Poison Chair" Treatment for multiple sclerosis. NEngl J Med 2012, 367:1149-1150.
48. Fox R.J., Miller D.H., Phillips J.T., et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer acetate in multiple sclerosis. NEngl J Med 2012, 367:1087-1097.
49. Kappos L., Gold R., Miller D.H. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler 2012, 18(3):314-321.
50. Phillips JT, Fox RJ, Selmaj K, et al. Long-term safety and tolerability of oral BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis: interim results from ENDORSE. In: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France October, 2012. p. 1103.
51. Ford C.C., Fox E.J. Assessing safety and potential risks of disease-modifying therapies for multiple sclerosis. The Science of MS Management 2012, 2(3):3-13.
52. Robertson N.P. Alemtuzumab for multiple sclerosis: a new age of immunotherapy. JNeurol 2013, 260:343-345.
53. Hill-Cawthorne G.A., Button T., Tuohy O., et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. JNeurol Neurosurgery Psychiatry 2012, 83:298-304.
54. Coles A.J., Compston D.A., Selmaj K.W., The CAMMS223 Trial Investigators, et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. NEngl J Med 2008, 359:1786-1801.
55. Coles A.J. Alemtuzumab more effective than interferon beta-1a at 5-year follow up of CAMMS223 clinical trial. Neurology 2012, 78:1069-1078.
56. Cohen J.A., Coles A.J., Arnold D.L., CARE-MS I Investigators, et al. Alemtuzumab versus interferon beta-1a as first line treatment for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012, 380:1819-1828.
57. Coles A.J., Twyman C.L., Arnold D.L., CARE-MS II Investigators, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012, 380:1829-1839.
58. Sprenger T., Kappos L. Alemtuzumab for multiple sclerosis: who and when to treat?. Lancet 2012, 380:1795-1797.
59. Polman C.H., O'Connor P.W., Havrdova E., et al. Arandomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. NEngl J Med 2006, 354:899-910.
60. Tan C.S., Koralnik I.J. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010, 9:425-437.
61. Yousry T.A., Habil D.M., Pelletier D., et al. Magnetic resonance imaging pattern in Natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012, 72:779-787.
62. Fox R.J., Rudick R.A. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 2012, 78:436-437.
63. Gorelik L., Lerner M., Bixler S., et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010, 68:295-303.
64. Bloomgren G., Richman S., Hotermans C., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. NEngl J Med 2012, 366:1870-1880.
65. Vermersch P., Kappos L., Gold R., et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011, 76:1697-1704.
66. Khatri B.O., Man S., Giovannoni G., et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009, 72:402-409.
67. O'Connor P.W., Goodman A., Kappos L., et al. Disease activity return to baseline during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011, 76:1858-1865.
68. Stefoski D, Balabanov R, Javed A, etal. Immunostimulatory effect of G-CSF is potentially beneficial In natalizumab-associated PML/IRIS. In: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France October, 2012.
69. Antoniol C., Jilek S., Schluep M., et al. Impairment of JCV-specific T-cell response by corticotherapy. Effect on PML-IRIS management?. Neurology 2012, 79:2258-2264.
70. Clifford D.B., De Luca A., Simpson D.M., et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010, 9:438-446.
71. Lenhard T., Biller A., Mueller W., et al. Immune reconstitution inflammatory syndrome after withdrawal of Natalizumab?. Neurology 2010, 75:831-833.
72. Rigau V., Mania A., Befort P., et al. Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology 2012, 79:2214-2216.
73. Smolders J., Damoiseaux J., Menheere P., et al. Vitamin D as an immune modulator in multiple sclerosis, a review. JNeuroimmunol 2008, 194:7-17.
74. Smolders J., Peelen E., Thewissen M., et al. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One 2010, 5:e15235.
75. Cantorna M.T. Vitamin D and multiple sclerosis: an update. Nutr Rev 2008, 66(Suppl 2):S135-S138.
76. McDowell T.Y., Amr S., Culpepper W.J., et al. Sun exposure, Vitamin D and age at disease onset in relapsing multiple sclerosis. Neuroepidemiology 2011, 36:39-45.
77. Munger K.L., Zhang S.M., O'Reilly E., et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62:60-65.
78. Farinotti M., Vacchi L., Simi S., et al. Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev 2012, (12). [review], CD004192.